BALAMINES
Balaji Amines Limited (BALAMINES) breaks out, gains 6% intraday
Balaji Amines Limited (BALAMINES) stock breaks out with a 6% intraday gain, clearing its 6-month resistance trendline. Current price: ₹2218.6.
Balaji Amines Limited (BALAMINES) breaks out with a +6% gain to ₹2218.6 on the NSE, clearing its 6-month resistance trendline. This move is driven by technical momentum as the stock surpassed the key resistance level of ₹1839, marking a 17.1% clear. In the specialty chemicals sector, BALAMINES’ breakout indicates strong technical performance, though it remains to be seen if this aligns with broader sector trends or is company-specific.
Technical setup — trendlines & DMA
The current trendline structure shows BALAMINES trading well above its 6-month support floor of ₹1912.9, currently standing 13.78% above this level. The resistance trendline at ₹1839.39 has been decisively broken, with the stock now 17.09% above this mark. The 50-DMA at ₹1777.8 is above the 200-DMA at ₹1332.4, indicating a bullish trend. BALAMINES is currently 18% above its 50-DMA, suggesting an extended move. Within its 52-week range of ₹968.1 to ₹2288.0, the stock is in the upper third, reflecting strong momentum but also indicating that a significant portion of the move may already be priced in.
Snapshot: ₹2,218.60 on 2026-07-02 (chart frozen at publication)
Fundamentals & business context
With a PE of 40.6, BALAMINES trades at a premium despite its profit margin of 11.7% and a revenue CAGR of -15.6% over the past five years. This suggests that the market may be pricing in a potential turnaround or that the valuation is stretched relative to current earnings. The low institutional holding of 2.3% indicates that smart money is cautious about this stock. There is no NSE catalyst today, and the move is purely technical.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak stock. The strongest signals include the bullish trend, with the 50-day average above the 200-day average, and the breakout above resistance levels with strong momentum. These indicators suggest that BALAMINES is in a positive technical phase. However, the weakest signals are the declining revenue and profit CAGRs, which highlight the company’s fundamental challenges. Additionally, the negligible dividend yield of 0.54% offers little income to investors, which could be a concern for those seeking regular returns.
Company outlook
Management provided forward-looking guidance indicating 25% to 30% volume growth in FY27 and EBITDA sustainability between 22% to 23% on total sales. The revenue target is set at INR3,000 crores by FY28. Capex for the current year is expected to be between INR275 crores to INR290 crores. The DME plant is anticipated to reach 30% to 40% utilization in FY27 and 50% to 60% by the end of the year. Key initiatives include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment is planned in a phased manner. The brownfield project for EDA-based value-added products is expected to be commissioned during H1 FY27, with greenfield projects at MIDC, Chincholi slated for Q4 FY27.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) gains 6% intraday
Balaji Amines Limited (BALAMINES) stock rises 6% intraday to ₹2172.1, showing a bounce from support despite a consolidating down trendline..
Balaji Amines Limited (BALAMINES) climbed +6% to ₹2172.1 on the NSE today, reflecting a technical bounce from support rather than a breakout. The stock has transitioned from a bounce from support to consolidating down, indicating a weak structure. This move is specific to BALAMINES and does not align with broader sector momentum in specialty chemicals.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows BALAMINES trading above the 6-month support trendline at ₹1959.04, which is 9.81% below today’s price, but well below the 6-month resistance trendline at ₹2525.35. The stock is currently in a breakdown phase, with the 50-DMA at ₹2154.9 above the 200-DMA at ₹1447.2, suggesting a positive but recovering trend. BALAMINES is trading in the upper third of its 52-week range, indicating that a significant portion of its move is already priced in.
Snapshot: ₹2,172.10 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 32.5 and profit margins at 13.4%, BALAMINES’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings do not justify the high PE ratio. Institutional ownership stands at a low 2.3%, indicating that smart money is cautious about this name. There was no NSE catalyst today driving the move.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak stock. The strongest signals include bullish sentiment with a 1.85x higher average volume on up days compared to down days, and a positive year-over-year gain of 32.2%. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.54% offers little income to investors, despite the company’s excellent financial health with a debt-to-equity ratio of 0.00.
Company outlook
Management outlined an optimistic forward guidance for BALAMINES, targeting a 25% to 30% volume growth in FY27 and sustaining EBITDA between 22% to 23% on total sales. The company aims to achieve a revenue target of ₹3,000 crores by FY28. Key growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, BALAMINES plans a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment and several greenfield and brownfield projects expected to be commissioned throughout FY27.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) gains 5% intraday
Balaji Amines Limited (NSE: BALAMINES) stock price rises 5% intraday to ₹2116.0, bouncing from support in the Basic Materials & Specialty Chemicals sector.
Balaji Amines Limited (BALAMINES) bounced from support today, gaining +5% to ₹2116.0 on the NSE. This move comes as the stock tests its 6-month support trendline, which is currently at ₹2117.13. Balaji Amines operates in the specialty chemicals segment within the basic materials sector. Today’s bounce aligns with the stock’s recovery mode, though it remains to be seen if this move will sustain given the broader sector trends.
Technical setup — trendlines & DMA
The current trendline structure for Balaji Amines shows a 6-month support floor at ₹2117.13, just 0.05% above today’s price. Resistance is at ₹2525.35, which is 19.35% above the current price. The 50-day moving average (DMA) is at ₹2136.1, indicating that the stock is currently below this level but above the 200-DMA at ₹1431.6. This suggests the stock is in recovery mode rather than extended above both DMAs. The stock is trading in the upper third of its 52-week range, indicating that a significant portion of the move may already be priced in.
Snapshot: ₹2,116.00 on 2026-08-06 (chart frozen at publication)
Fundamentals & business context
With a PE of 33.5, profit margins at 13.4%, and a revenue CAGR of -15.6%, Balaji Amines’ valuation appears stretched relative to its current earnings. The market may be pricing in a potential turnaround, given the company’s ambitious growth targets. Institutional ownership stands at a low 2.3%, suggesting that the smart money is cautious about this name. There was no NSE catalyst today, making this move primarily technical.
Algorithmic scorecard
The overall algorithmic score of 56 reflects a technically strong but fundamentally weak profile for Balaji Amines. Two of the strongest signals are the bullish trend, indicated by the 50-DMA being above the 200-DMA, and the bullish sentiment over the last 30 days, where the stock has seen 14 up days versus 16 down days with a volume ratio of 1.89x. These signals suggest systematic accumulation and positive market sentiment. However, the company faces risks from its declining revenue and profit CAGRs, which stand at -15.6% and -19.9% respectively. Additionally, the negligible dividend yield of 0.52% offers little income for investors, making the stock more reliant on capital appreciation.
Company outlook
Management outlined an optimistic forward guidance for Balaji Amines, targeting 25% to 30% volume growth in FY27 and aiming to maintain EBITDA between 22% to 23% on total sales. The company has set a revenue target of ₹3,000 crores by FY28 and plans a capital expenditure of ₹275 crores to ₹290 crores for the current year. Growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, expected to reach 30% to 40% utilization by FY27 and 50% to 60% by the end of the year. Additionally, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity is expected to be commissioned during FY27, along with an improved process-based Acetonitrile (ACN) plant in Q2 FY27. The company also plans a major expansion of Balaji Specialty Chemicals Limited with an investment of ₹750 crores in a phased manner.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) falls 5% intraday, breaks below support
Balaji Amines Limited (NSE: BALAMINES) drops 5% intraday to ₹2125.6, breaking below crucial support in the Specialty Chemicals sector.
Balaji Amines Limited (BALAMINES) breaks below support, falling -5% to ₹2125.6 on the NSE on 31 Jul 2026. The move comes as the stock has breached its 6-month support trendline, signaling a breakdown in the short-term trend. Balaji Amines operates in the specialty chemicals segment within the basic materials sector, and today’s decline appears to be company-specific rather than a sector-wide phenomenon.
Technical setup — trendlines & DMA
The current 6-month support trendline for Balaji Amines was at ₹2436.56, and the stock has fallen 14.63% below this level, indicating a breakdown. Resistance is at ₹2525.35, which is 18.81% above the current price. The 50-DMA is at ₹2113.0, slightly below today’s price, while the 200-DMA is at ₹1419.4, showing a significant 58.05% increase from this longer-term average. The stock is currently in the upper third of its 52-week range, suggesting that a substantial portion of its yearly highs is still priced in.
Snapshot: ₹2,125.60 on 2026-07-31 (chart frozen at publication)
Fundamentals & business context
With a PE of 35.7 and profit margins at 13.4%, Balaji Amines’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings and growth trajectory suggest a cautious approach. Institutional ownership stands at a mere 2.3%, indicating that the ‘smart money’ is not heavily invested in this name. There was no specific NSE catalyst today to explain the move.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Balaji Amines. The strongest signals include a bullish trend, with the 50-day average above the 200-day average, and bullish sentiment over the last 30 days, where up days saw 2.24 times the volume of down days. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.48% offers little income for investors, while the high public ownership of 41.57% suggests higher volatility risk.
Company outlook
Management has provided forward-looking guidance indicating 25% to 30% volume growth in FY27 and EBITDA sustainability between 22% to 23% on total sales. The company targets INR3,000 crores in revenue by FY28 and plans a capital expenditure of INR275 crores to INR290 crores for the current year. Growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment is planned in a phased manner.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) USFDA Inspection Concludes at Ahmedabad Plant
-
Basic Materials3 days agoEllenbarrie Industrial Gases Limited Secures ₹481 Crore Air Separation Unit Contract
-
GESHIP3 days agoThe Great Eastern Shipping Company Limited (geship) Contracts to Buy a New-building Suezmax Tanker
-
ANURAS3 days agoAnupam Rasayan India Limited Completes Acquisition of Bliss GVS Pharma, Marks Third Strategic Step
-
Aluminum3 days agoNational Aluminium Company Limited (nationalum) Announces Record Dividend Payment for FY 2025-26
-
Consumer Cyclical3 days agoLandmark Cars Expands Footprint with BYD and Mahindra & Mahindra
-
ARIS2 days agoArisinfra Solutions Limited (aris) Secures Second Transcon Mandate for ₹400 Cr GDV Project in Kalina
-
Consumer Cyclical2 days agoCosmo FIRST Limited (NSE: Cosmofirst) Zigly Pet Care Expands Veterinary Care Footprint with Acquisition of Leading Speciality Vet Clinic